CLIMB BIO ANNOUNCES FDA FAST TRACK DESIGNATION FOR BUDOPRUTUG FOR THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY
CLIMB BIO INC - TO SHARE INITIAL PHASE 2 DATA IN SECOND HALF OF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.